In an apparent case of first impression, a Philadelphia judge has ruled that two pharmaceutical companies may have a legal duty to class members for money spent on the generic version of the companies' name-brand drug allegedly marketed by the companies for uses not approved by federal regulators. The generic drug in the case was produced by a third-party manufacturer.
Drug Companies on the Hook for Off-Label Use of Generic
The Legal Intelligencer
March 24, 2008
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.